Eyenovia Shares Look 38% Higher on Development Deal with Arctic Vision in Asia August 12, 2020 (Investorideas.com Newswire) Shares of Eyenovia Inc. set a new 52-week high after the firm reported it entered into an exclusive collaboration and license agreement with Arctic Vision to develop and market MicroPine and MicroLine in China and South Korea.

Moderna (Nasdaq: $MRNA) Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) CAMBRIDGE, Mass - August 12, 2020 (Investorideas.com Newswire) Coronavirus / Biotechnology (COVID-19) Stock News Bites - Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that the U.S. government has secured 100 million doses of mRNA-1273 as part of the U.S. government's goal of securing early access to safe and effective COVID-19 vaccines for the American people.

Is Summit's Ridinilazole a Threat to Acurx's Ibezapolstat in the C.difficile Space? August 11, 2020 (Investorideas.com Newswire) Dr. KSS, the founder and editor-in-chief of BioPub.co, compares the two drugs as potential treatments for C. difficile.

$18.5 Billion Merger Could Mean Big Gains for These Five Tiny Telemedicine Stocks August 11, 2020 (Investorideas.com Newswire) Independent financial analyst Matt Badiali examines five small companies poised to profit as digital health becomes mainstream during the coronavirus pandemic.

Seres Therapeutics Shares Go Parabolic on Positive Topline Data from Phase 3 C.Diff Trial August 11, 2020 (Investorideas.com Newswire) Seres Therapeutics shares traded 350% higher setting a new 52-week high after the firm reported positive topline results from its SER-109 Phase 3 ECOSPOR III study in recurrent C. difficile infection.

Biotech / Covid-19 Stock News: Novavax (Nasdaq: $NVAX) and Takeda Announce Collaboration for Novavax' COVID-19 Vaccine Candidate in Japan Gaithersburg, MD, and Osaka, Japan - August 7, 2020 (Investorideas.com Newswire) Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX CoV2373, Novavax' COVID 19 vaccine candidate, in Japan.

US Immunology Firm Lands Government Contract, Raises Cash August 6, 2020 (Investorideas.com Newswire) These two CytoSorbents events are discussed in a Dawson James report.

Fulgent Genetics' Shares Reach New 52-Week High After Posting 105% Increase in Q2 Revenue August 6, 2020 (Investorideas.com Newswire) Shares of Fulgent Genetics traded 22% higher after the company reported it posted a record $17.1 million in Q2/20 revenue and completed a record 180,513 billable tests in the quarter.

Biotech / Covid-19 Stock News: Novavax (Nasdaq: $NVAX) to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020 Gaithersburg, MD - August 6, 2020 (Investorideas.com Newswire) Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, August 10, 2020.

Telemedicine Stock News: Teladoc Health ( $TDOC) and Livongo ( $LVGO) Merge to Create New Standard in Global Healthcare Delivery, Access and Experience PURCHASE, NY and MOUNTAIN VIEW, Calif. - August 5, 2020 (Investorideas.com Newswire) Teladoc Health (TDOC), the global leader in virtual care, and Livongo (LVGO), the leading Applied Health Signals company - today announced that they have entered into a definitive merger agreement. This merger represents a transformational opportunity to improve the delivery, access and experience of healthcare for consumers around the world.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Does Income Protection Cover Me for a COVID Redundancy?

August 10, 2020 (Investorideas.com Newswire) No one anticipated that 2020 would be marked by the arrival of a worldwide pandemic.

Everything You Need to Know About Investing in Healthcare Stocks

March 30, 2020 (Investorideas.com Newswire) Healthcare is one of the most favorable areas for stock investors, mainly because of the roughly $7 trillion that's invested in it across the world - in a single year.

The Rise Of The At-Home Testing Market

January 16, 2020 (Investorideas.com Newswire) Have you heard the term personalized medicine? It's the buzzword in use today thanks to the increase in medical tests being conducted at home.

Why Do You Need Birth Injury Lawyer and How They Can Help You?

October 2, 2019 (Investorideas.com Newswire) Childbirth injury is inexcusable. From the moment a child is conceived to the time the delivery is done, it is the responsibility of the doctors to see that the child is delivered with the utmost care and is healthy.

5 Key Tips For Renting a Boardroom

August 14, 2018 (Investorideas.com Newswire) You've arranged to rent virtual offices in Toronto from time to time.

How to Go About Choosing a Medical Malpractice Lawyer

February 13, 2018 (Investorideas.com Newswire) Medical malpractice affects thousands of individuals around the world. If you think you have been injured, or wrongfully treated by a medical professional, you may be entitled to compensation.

Media Central Corporation Inc. Completes Shares for Debt Transaction Toronto, Ontario--(Newsfile Corp. - January 31, 2020) - Media Central Corporation Inc. (CSE: FLYY) (FSE: 3AT) ("MediaCentral" or the "Company") reports that its Board of Directors has approved the settlement of $271,200 in aggregate of debt through the issuance of common shares of the Company (the "Debt Settlement"). Pursuant to the Debt Settlement, MediaCentral would issue 3,190,588 common shares of the Company (the "Shares") at a deemed price of $0.085 per Share to certain creditors...

American Aires Announces Agreement with Answer 365 and to Partner with Four Fulfillment Centers Toronto, Ontario--(Newsfile Corp. - January 31, 2020) - American Aires Inc. (CSE: WIFI) (the "Company" or "Aires") is pleased to announce that it has entered into a call centre service agreement (the "Service Agreement") effective January 28, 2020 with Answer 365, a Canadian call center, pursuant to which Answer 365 will outsource Aires' customer service providing 24-hour support and increased purchase satisfaction for Aires' customers around the world.. The Service Agreement may be terminated by...

EGF Theramed Announces Change of Directors and New CEO Vancouver, British Columbia--(Newsfile Corp. - January 30, 2020) - EGF Theramed Health Corp. (CSE: TMED) has appointed David Bentil and Jatinder Dhaliwal to the board of EGF Theramed Health Corp. Mr. Bentil will assume the role of CEO and Mr. Dhaliwal will assume the role of director. Mr. Bentil is an Economist by trade. In 2002, he decided to follow his passion by pursuing a career in the car business which has done for over...

Rainmaker Worldwide and Pi Eco Announce a Strategic Investment and Global Reseller Agreement Peterborough, Ontario--(Newsfile Corp. - January 30, 2020) - Rainmaker Worldwide Inc. (OTC Pink: RAKR) is extremely pleased to announce a comprehensive strategic investment by Pi Eco USA (www.pi.eco). This investment brings working capital for Rainmaker to fuel growth and upcoming deployments.In addition to the 500,000 USD capital injection, Pi Eco provides distributor and executive synergies that will be invaluable to Rainmaker and Pi Eco. Pi Eco has well-developed strategic relationships in Asia, Middle East, Central...

Cell MedX Corp. Reacquires World Wide Exclusivity Rights for the eBalance(R) Device Carson City, Nevada--(Newsfile Corp. - January 30, 2020) - Cell MedX Corp. (OTCQB: CMXC) (MUN: 9CX) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the Company has repurchased the worldwide exclusive direct rights for distribution of its eBalance® devices.Cell MedX identified two distribution market channels for sales of the eBalance® device, individual rights for home...

Subscribe to Biotech News